EXACT Sciences Corp (NASDAQ:EXAS)

CAPS Rating: 2 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Results 1 - 20 of 46 : 1 2 3 Next »

Recs

0
Member Avatar pchop12316 (87.09) Submitted: 11/19/2014 11:14:25 AM : Underperform Start Price: $22.78 EXAS Score: -7.02

not impressed with developments

Recs

1
Member Avatar ELPastor (39.70) Submitted: 10/27/2014 1:36:37 PM : Outperform Start Price: $23.11 EXAS Score: +0.96

Most people, it is safe to say, do not enjoy getting a colonoscopy. Therefore, any company that offers a non-invasive colorectal cancer screening test has a good chance of squeezing out a nice, large profit.

Recs

1
Member Avatar carterhiggins (76.26) Submitted: 10/20/2014 1:32:26 PM : Outperform Start Price: $23.83 EXAS Score: -5.80

Medicare reimbursement rate of 504 / test!!!

Recs

1
Member Avatar PODS100 (< 20) Submitted: 10/15/2014 4:16:40 PM : Outperform Start Price: $23.02 EXAS Score: -6.09

Proven by the Mayo clinic. Strong reimbursement rates from Medicare are approved at $502 per test, and market will be between 2 million to 8 million tests per year.

Recs

4
Member Avatar LarryMDR (37.80) Submitted: 8/25/2014 1:58:59 AM : Outperform Start Price: $19.95 EXAS Score: +19.39

Huge advance in colonrectal cancer detection that will obviate the need for a colonostophy. This test will be BIG! It saves money ($2,500 vs $500), saves the patient the VERY unpleasant experience of a colonsoptophy an it is highly accurate.

Recs

2
Member Avatar lectrician (< 20) Submitted: 8/19/2014 1:32:45 PM : Outperform Start Price: $17.73 EXAS Score: +32.74

Favorable CMS pricing decision should be coming soon.

Recs

1
Member Avatar Paythebills (< 20) Submitted: 8/12/2014 3:11:24 PM : Outperform Start Price: $17.38 EXAS Score: +34.86

According to reports this non-invasive proceedure can detect 90% of stage 1 and stage 2 colorectal cancers at an early treatable stage. FDA has just approved it.
With a low 10% false positives and its low cost when compared with colonoscopy. It looks like a winner as we look for cheaper ways to provide quality care.

Recs

0
Member Avatar gunterle (66.20) Submitted: 8/12/2014 12:08:25 PM : Outperform Start Price: $17.86 EXAS Score: +30.96

signal

Recs

0
Member Avatar drewvogel (63.24) Submitted: 6/17/2014 7:48:59 PM : Outperform Start Price: $16.52 EXAS Score: +43.00

FDA approval seems inevitable. Even if their current sales channel fails to fully mature or their reimbursement rate falls too low the current price is low enough to make them an acquisition candidate.

Recs

0
Member Avatar LowEnterpriseVal (< 20) Submitted: 5/17/2014 11:10:02 PM : Outperform Start Price: $12.29 EXAS Score: +90.43

On the rec of Kirk Spano. Upon FDA approval and subsequent execution of business plan, they will have a way to prevent most of the 50,000 yearly deaths due to colorectal cancers not found early enough. This is the 2nd most deadly cancer and yet also the most preventable with screening as it can take ten full years to develop. Market is large and the company may also develop other stool based tests for detecting other forms of cancer, opening more markets and more importantly saving more lives. Strong and experienced management and strong balance sheet.

Recs

0
Member Avatar benyboy (< 20) Submitted: 3/4/2014 10:09:31 PM : Outperform Start Price: $14.20 EXAS Score: +63.40

jim cramer

Recs

0
Member Avatar GirlsUnder30 (93.76) Submitted: 9/6/2013 7:47:57 PM : Outperform Start Price: $12.10 EXAS Score: +83.39

Hoping their participation at the Baird conference yields some business partnerships.

Recs

0
Member Avatar gowvu84 (35.96) Submitted: 9/5/2013 11:50:23 AM : Underperform Start Price: $12.27 EXAS Score: -76.39

Look at their product. Who will really use this?

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 5/1/2013 3:07:10 AM : Underperform Start Price: $9.14 EXAS Score: -140.22

Thanks to Portefeuille I caught a nice rebound on Exact last week as a negative reaction to the DeeP-C data mysteriously reversed itself. I still have 100 shares of the stock with cost basis 7 that I'm just waiting for Portefeuille to tell me what to do with, but it isn't enough of a position to stop me from betting against it in CAPS. A 600M market cap is way too much for unconvincing sensitivity and specificity data that don't provide a convincing basis for widespread adoption of the Cologuard test. Exact is once again a trader's football and I expect the stock to move with the winds until a concrete catalyst emerges.

Recs

3
Member Avatar NHWeston102 (64.57) Submitted: 4/19/2013 8:45:35 AM : Outperform Start Price: $8.73 EXAS Score: +148.65

Fallen too far. Once FDA approves, EXAS will become much more competitive and might get bought.

Recs

0
Member Avatar drmanand (66.83) Submitted: 1/14/2013 8:53:31 PM : Outperform Start Price: $11.46 EXAS Score: +73.68

Very important screening test

Recs

0
Member Avatar foolfully (58.40) Submitted: 11/21/2012 4:20:06 PM : Outperform Start Price: $9.28 EXAS Score: +118.09

100

Recs

0
Member Avatar JonBarleycorn (73.02) Submitted: 10/31/2012 3:11:43 AM : Outperform Start Price: $9.20 EXAS Score: +122.21

The graying of America makes one high on pharmaceuticals.

Recs

1
Member Avatar TLStockPicks (92.28) Submitted: 9/5/2012 10:28:21 AM : Outperform Start Price: $10.55 EXAS Score: +88.58

Boomers getting old.
"Can I stick this in your butt?"
"No, but here's some poo."

Recs

3
Member Avatar Troy2008 (96.42) Submitted: 7/21/2012 12:34:03 PM : Outperform Start Price: $10.00 EXAS Score: +95.81

Blood based tests don't find PRE-CANCERS with any amount of accuracy. The ColoGuard(EXAS) test is done in your own home in 1 minute, no doctor, no office visit, no needle stuck in your arm. The accuracy of the stool based DNA test is far better than any blood based test.

10,000 person Phase 3 FDA/Mayo clinic validation study will be complete in this quarter for top line results reported in Q4 THIS year.

Results 1 - 20 of 46 : 1 2 3 Next »

Featured Broker Partners


Advertisement